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Background: The level of platelet inhibition by a Glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist
therapy necessary to minimize thrombotic complications in patients undergoing percu-
taneous coronary intervention (PCI) is a subject of debate. The degree of platelet inhibition
obtained 10 min after start of GpIIb/IIIa antagonist therapy predicts adverse events after PCI.
The aim of this study was to look at platelet inhibition and to compare platelet GpIIb/IIIa
receptors occupancy ratio (GpRO) with Eptifibatide and Tirofiban using various dose regi-
mens and correlate with 30-day clinical outcomes in patients presenting with high-risk
acute coronary syndromes (ACS) and undergoing PCI.
Methods: The patients were divided into four sub groups: (1) Eptifibatide two intracoronary
bolus (180 mg/kg) alone (EB); or (2) two intravenous bolus (180 mg/kg) followed by infusion at
2 mg/kg/min for 24 h (EB þ Inf); and (3) Tirofiban standard bolus dose (0.4 mg/kg) over 30 min
followed by infusion at 0.1 mg/kg/min (TStd); or (4) at ADVANCE dose bolus (25 mg/kg) over
3 min, followed by infusion at 0.1 mg/kg/min (TAdv). Number of GpIIb/IIIa receptors was
assessed by flow cytometry at baseline and 10 min after the bolus and percentage of free
receptors was determined to calculate the GpRO. Patients were followed for 30 days for any
major adverse cardiac events (MACE).
Results: 200 consecutive patients (including 74% with ST-elevation ACS) were enrolled.
GpRO in groups EB (n ¼ 48) and EB þ Inf (n ¼ 44) were 62.7%  27.2% and 61.4%  6.1%
respectively while in the groups TStd (n ¼ 96) and TAdv (n ¼ 12) groups were 35.1%  17.74%
and 68.8%  27.3% respectively. The GpRO was similar in EB, EB þ Inf and TAdv groups and
was significantly higher than TStd group (p < 0.0001). The 30-day MACE rates in EB (4.2%),
EB þ Inf (4.5%) and TAdv (4.2%) were significantly lower than TStd group (12.5%) (p < 0.01).(A. Puri).
2012, Cardiological Society of India. All rights reserved.
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 1 5 2e1 5 7 153Conclusions: Standard dose Tirofiban results in significantly lower rates of GpIIb/IIIa receptor
occupancy ratio and this correlated with higher incidence of 30-day MACE in high-risk ACS
patients undergoing PCI.
Copyright ª 2012, Cardiological Society of India. All rights reserved.1. Introduction receiving a GpIIb/IIIa receptor antagonist therapy in the form ofThe level of platelet inhibition induced by a Glycoprotein IIb/IIIa
(GpIIb/IIIa) receptor antagonist therapy necessary to minimize
thrombotic complications in patients undergoing percutaneous
coronary intervention (PCI) has been the subject of various
studies. Steinhubl et al, in the GOLD study, showed that the
degree of platelet function inhibition obtained 10 min after the
start of GpIIb/IIIa receptor antagonist therapy is an independent
predictor of the risk of major adverse cardiac events after PCl.1
It has been shown that the extent of inhibition of platelet aggre-
gation depends on various factors like, (1) the clinical presenta-
tion, (2) the typeof antiplatelet agentsusedand (3) thedoseof the
antiplateletagent.However, considerable interpatientvariability
in the platelet inhibitory response has been observed in various
studies. The effort to achieve and sustain optimal receptor
blockade had led to various adjustments in the weight-based
dosing strategies of the different GpIIb/IIIa receptor antagonist
drugs namely Abciximab, Eptifibatide and Tirofiban. Initial dose
finding trials in humans attempted to identify the appropriate
dosing regimennecessary toachieveandmaintain>80%GpIIb/IIIa
receptor blockade, or achieve <20% of baseline ADP induced
platelet aggregation. Early studies found that inhibition ofw50%
of GpIIb/IIIa receptors was needed to detect significant inhibition
of ADP induced platelet aggregation, whereas blockade of >80%
of the receptors completely abolished ADP induced platelet
aggregation, suggesting a steep doseeresponse curve.2,3
Quantitative flow cytometry allows platelet membrane
receptor measurement in whole blood samples and Glyco-
protein IIb/IIIa receptor occupancy (GpRO) ratio can be
measured either directly or indirectly. Markers of platelet
activation have been studied with flow cytometry to predict
an increased risk of ischemic events after PCI. It has been
shown that higher levels of platelet GpRO with Eptifibatide
have been associated with improved myocardial perfusion
among patients with ST-elevation myocardial infarction. It
has also been shown that intracoronary administration of
Eptifibatide results in a high local concentration, which in turn
may lead to increased levels of platelet GpRO, cause more
destabilization of platelet aggregates, and promote thrombus
disaggregation, thereby improving myocardial perfusion.4,5
The aim of this study was to compare the platelet GpIIb/IIIa
receptors occupancy ratio with Eptifibatide and Tirofiban
using flow cytometry and to correlate with 30-day clinical
outcomes in patients undergoing PCI for established clinical
indications also being treated with GpIIb/IIIa receptor antago-
nist therapy.2. Methods
We included all consecutive patients admitted to our hospital
undergoing PCI for an acute coronary syndrome (ACS) andeither Eptifibatide or Tirofiban based on the treating clinician’s
discretion. The indexdiagnosis ofACS includedunstableangina,
noneST-elevation myocardial infarction (NSTEMI), or ST-
elevation myocardial infarction (STEMI). All STEMI patients
includedweretreatedasperbestprevailing indications including
with thrombolytic therapyanddecision for PCIwas based on the
physician’s discretion, which in turn was based on current best
clinical practice with most patients having routine angiography
within 24 h and proceeding for PCI if needed. The exclusion
criteria weremultivessel PCI at the time of the index procedure;
severe coronary calcification; unprotected left main stenosis
>50%; target lesion in a saphenous vein graft; previous stenting
at the target lesion; or a contraindication to GpIIb/IIIa receptor
antagonist therapy. The age, sex, detailed clinical history
including that of diabetes mellitus, smoking, hypertension,
family history of coronary artery disease (CAD), hospitalization
for CAD were noted. At admission a thorough clinical examina-
tion including measuring the body weight (Wt), pulse rate (PR),
systolic blood pressure (SBP), determination of Killip class (KC),
and an electrocardiogram (ECG) was done. In addition to this,
TroponinT, lipidprofile, platelet count before and after PCI, CPK-
MB theday followingPCIwerealso recorded. 2DEchocardiogram
was done for determination of left ventricular ejection fraction
(EF)usingSimpson’smethod,alongwithLVenddiastolicandend
systolic volume noted. Informed consent for participation in the
study was obtained by all patients prior to enrollment.
During PCI, all of the patients were treated as per protocol
with at least 325mgaspirin before theprocedure.A loadingdose
of Clopidogrel 300 mg was administered prior to the PCI. A
weight-adjusted heparin regimen was used to titrate and ach-
ieve aminimumactivated clotting timeof 250 s. Guidewires and
approved stents (drug-eluting or bare metal) were used accord-
ing to standard techniques and based on the performing physi-
cian’s discretion. Stent was deployed after completion of the
bolus dose of GpIIb/IIIa receptor antagonist therapy, and choice of
drug [Eptifibatide (Group E) or Tirofiban (GroupT)]was left to the
performing physicians discretion and hence the study was not
randomized or blinded to one treatment or another upon
enrollment. Each groupwas further divided into two subgroups
each based on the dose regimen used viz (1) Eptifibatide two
intracoronary bolus (180 mg/kg) alone (EB); or (2) two intravenous
bolus (180mg/kg) followedby infusionat2mg/kg/min(EBþ Inf); and
(3) Tirofiban standard dose (TStd) (0.4 mg/kg bolus over 30 min)
followedby0.1mg/kg/mininfusion;or (4)atADVANCEdose (TAdv)
(25 mg/kg bolus over 3min), followedby infusion at 0.1mg/kg/min
based on the dose used in the ADVANCE trial.63. Platelet aggregometry study
Tenml blood samples were taken in 3.8% sodium citrate vials,
at baseline from the catheter prior to engaging the coronary
Table 1 e Baseline characteristics of patients (n[ 200).
Patient
demographics
Eptifibatide
(n ¼ 92)
Tirofiban
(n ¼ 108)
Mean age 53 52
Male 76 96
Female 16 12
Diabetes mellitus 24 16
Hypertension 40 24
Dyslipidemia 32 32
Smoker 40 60
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Tirofiban 10 min after starting the infusion. Samples were
analyzed at an ISO 9001:2000 and NABL certified laboratory by
flow cytometry using platelet GpIIb/IIIa Occupancy kit (PLT
VASP/P2Y12, Biocytex, Marseille, France). At baseline, the
numbers of GpIIb/IIIa receptor/cell were calculated and the
percentage of free receptors was determined. With the 2nd
sample, again percentage of free and bound receptors was
calculated and subsequently GpIIb/IIIa receptor occupancy
(GpRO) ratio was determined. The flow cytometric method is
based on binding of two monoclonal antibodies to platelet
GpIIb/IIIa viz Mab1 and Mab2. Monoclonal antibody 1 (Mab 1,
Clone L4P18) is a murine monoclonal antibody to GpIIb/IIIa
complex and the monoclonal antibody 2 (Mab 2, Clone 4F8) is
a murine monoclonal antibody to beta 3 subunits. Binding of
these antibodies is used in a flow cytometric assay to directly
quantify occupied and unoccupied Glycoprotein IIb/IIIa
receptors. Eptifibatide binds with Mab 2 in a dose-dependent
manner and has little effect on Mab 1 binding while Tirofiban
binds with bothMab 1 andMab 2. The total number of platelet
GpIIb/IIIa receptors and number of free GpIIb/IIIa receptors are
determined by converting the fluorescence intensity into the
corresponding numbers of sites per platelet base on a cali-
brated bead standard curve. The final GpRO results for each
patient were blinded till the end of study period.
Major adverse clinical event (MACE) end points of recurrent
ischemia, reinfarction, target vessel revascularization, wors-
ening heart failure, repeat hospitalization for cardiovascular
(CV) causes and CV Death during these 30 days were recorded.
Worsening heart failure was defined as a worsening in Killip’s
class of more than one grade. Recurrent ischemia was defined
as those who had a worsening of NYHA functional class of
more than one grade during the 30 days and required a step
up of anti-anginal therapy. Those who could not be stabilized
on medical therapy and required hospitalization either for
recurrent ischemia or worsening heart failure, were included
in the group of repeat hospitalizations. The entire study was
cleared by the ethics committee of the university and con-
formed to the guidelines set for good clinical practice.
3.1. Statistical analysis
SPSS 11.5 software was used for analysis of the data obtained.
The student t test, Fisher’s exact test and Chi square test were
used to test the significance between the study groups. Risk
analysis was carried out by calculating the odds ratio (OR) and
95% confidence interval (CI).
Indications of PCI
USA 0 8
NSTEMI 12 32
STEMI 80 68
AWMI 56 20
IWMI 24 48
Urgency of PCI
Elective PCI 72 96
Primary PCI 12 8
Rescue PCI 8 4
PCI ¼ Percutaneous Coronary Intervention; USA ¼ unstable angina;
NSTEMI ¼ noneST-elevation myocardial infarction; STEMI ¼ ST-
elevation myocardial infarction; AWMI ¼ Anterior Wall myocardial
infarction; IWMI ¼ Inferior Wall myocardial infarction.4. Results
Two hundred consecutive patients were enrolled in the study.
The mean age of the patients was 53 years. The index event
and indication of PCl was ST-elevation myocardial infarction
(STEMI) in 74% (38% with anterior wall myocardial infarction
(AWMI), 36% with inferior wall myocardial infarction (IWMI));
noneST-elevationmyocardial infarction (NSTEMI) in 22%, and
unstable angina 4%; in the STEMI group 10% patients had
primary PCI and 6% had rescue PCI following failed
thrombolysis.Among the cohort 20% patients were diabetic, 32% were
hypertensive, 32% had dyslipidemia, 50% were smokers and
38% patients had 2 risk factors. The mean level of troponin
T elevation on admission was 2.25 ng/ml. Baseline charac-
teristics of the patient’s are shown in Table 1.
Based on the drugs used the patients were divided into two
groups i.e. the Eptifibatide group (Group E) and the Tirofiban
group (Group T) and further subdivided into four subgroups
i.e., (1) Eptifibatide two intracoronary bolus alone (Group EB)
which included 48 patients; (2) Eptifibatide intravenous bolus
followed by infusion (Group EB þ Inf) which included 44
patients; (3) Tirofiban standard dose group (TStd) which
included 96 patients; and (4) Tirofiban ADVANCE dose (Group
TAdv) which included 12 patients.
4.1. GpIIb/IIIa occupancy ratio
The average numbers of GpIIb/IIIa receptors/cell at baselinewas
73,379  12,426 in the entire cohort. Based on patients
risk factors in the diabetic subgroup the average number of
GpIIb/IIIa receptors/cell was 75,200  10,115; in hypertensive
patients it was 71,437  11,225; in smokers it was
72,920  10,246; and in the dyslipidemia group it was
76,687  10,356. At baseline 6.12%  8.62% GpIIb/IIIa receptors
were occupied, which could be attributed to receptor binding
with fibrinogen and von Willebrand factor. The GpRO ratio
above baseline in Group E was 70.25%  19.11% while in the
Group T was 38.20%  20.74% (p < 0.001).
The absolute GpRO was significantly higher with Group E
62.1%  17.1% as compared to Group T 38.8%  18.8%
(p < 0.001). Across all patient risk groups Eptifibatide achieved
significantly higher GpRO as compared with Tirofiban viz, in
diabetic patients 61.16%  26% v/s 38.53%  22.23% (p < 0.05);
in hypertensive patients 56.82%  21.56% v/s 37.57%  22.89%
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30.85%  17.31% (p < 0.05); while there was a non-significant
increase in GpRO with Eptifibatide in smokers as compared
to Tirofiban 53.31%  23.69% v/s 43.72%  18.02% (Table 2). In
the presence of visible thrombus the GpRO was significantly
lower as compared to without visible thrombus in Group E
with visible thrombus 56.24%  22.96% v/s 75.74%  13.24%
with no visible thrombus (p< 0.01); and in Group Twith visible
thrombus 29.60%  18.7% v/s 41.20%  18.84% with no visible
thrombus (p < 0.01).
The GpRO based on the index event of the patient was
51.12%  23.75% in the STEMI patients; 38.61%  22.74% in the
NSTEMI patients and 63.23%  18.7% in the unstable angina
patients. Interestingly, there was a trend of increased GpRO in
patients having platelet count greater than 250,000. The GpRO
achieved according to weight showed significantly higher
GpRO in the patients having less than 60 kg body weight in
Group E 67.77%  27.74% v/s 59.78%  19.74% (p < 0.05) and in
Group T 46.77%  20.13% v/s 31.56%  17.16% (p < 0.05).
In the subgroup EB absolute GpRO was 62.7%  27.2% while
in the subgroup EB þ Inf absolute GpRO was 61.4%  6.1%;
whereas in subgroup TStd absolute GpRO was 35.1%  17.74%
and in subgroup TAdv was 68.8%  27.3%. Therefore the
absolute GpRO was similar in subgroups EB, EB þ Inf and TAdv
groups which was significantly higher than TStd group
(p < 0.001). The percentage of patients achieving >80% GpRO
was only seenwith 13% in the EB þ Inf group, 9% in the EB group,
8% in the TAdv group and in none of the patients in the TStd
group. There was no difference in any bleeding side effects
across all four subgroups following the procedure.
The incidence of 30-day MACE rates in Group E was 4.3%
(subgroup EB 4.2% and subgroup EB þ Inf 4.5%), while in Group T
was 13% (subgroup TAdv 8.3% and subgroup TStd 12.5%). There
was a trend for MACE to be lower with Eptifibatide as
compared to Tirofiban although this did not reach statistical
significance (p¼ 0.06). MACE rateswere lower in EB, EB þ Inf and
TAdv subgroups than TStd subgroup, however this did not
reach statistical significance (Table 3).5. Discussion
Glycoprotein IIb/IIIa receptor antagonists have been shown
to therapeutically down regulate platelet function to preventTable 2 e Glycoprotein IIb/IIIa receptor occupancy ratio and 30
(Group E) and Tirofiban group (Group T).
Results Group E, n ¼ 92
GpRO above baseline 70.3%  19.1%
Absolute GpRO 62.1%  17.1%
GpRO >80% achieved 11%
GpRO in diabetic 61.2%  26% (n ¼ 24)
GpRO in hypertensive 56.8%  21.6% (n ¼ 40)
GpRO in dyslipidemia 67.6%  13.5% (n ¼ 32)
GpRO in smokers 53.3%  23.7% (n ¼ 40)
30-Day MACE 4.3%
GpRO ¼ Glycoprotein IIb/IIIa receptor occupancy; MACE ¼ Major adverse
vessel revascularization, worsening heart failure, repeat hospitalizationthe thrombotic complications associated with coronary
artery disease.7 However, several individual studies, in
specific patient populations or with suboptimal dosing regi-
mens, have found a lack of effect in preventing thrombotic
complications.8 These results raise the question as to
whether a specific dose of GpIIb/IIIa receptor antagonist,
adjusted only by patient weight, can provide the same level
of platelet inhibition across all clinical syndromes and across
all individuals.
The GOLD multicenter study,1 showed that patients who
did not achieve >95% inhibition of GpIIb/IIIa receptors after
bolus of GpIIb/IIIa receptor antagonist therapy experienced
a significantly higher incidence of MACE rates (14.4% v/s 6.4%,
p ¼ 0.006). Patients whose platelet function was <70% inhibi-
ted at 8 h after the start of therapy had a MACE rate of 25% v/s
8.1% for those with >70% inhibition of platelet function
(p ¼ 0.009) and on multivariate analysis it was found that
platelet function inhibition >95% at 10 min after the start of
therapy was associated with a significant decrease in the
incidence of MACE. However, in our study only 7% of patients
in the entire cohort achieved >80% GpRO (13% in the EB þ Inf
group, 9% in the EB group, 8% in the TAdv group and in none of
the patients in the TStd group) which may indicate suboptimal
drug effect or variation in pharmacological response in our
population.
It has been suggested that the disaggregation of platelet
thrombi may be a mechanism for the clinical benefits. Eptifi-
batide has demonstrated to reduce the occurrence of myo-
necrosis with PCI in acute coronary syndromes, a clinical
scenario associated with platelet rich thrombus development.
In an analysis of the Enhanced Suppression of the Platelet IIb/
IIIa Receptor With Integrilin Therapy (ESPRIT) trial, patients
were then stratified into high- and low-risk groups in which
thrombotic complications with the PCI were more likely
during revascularization. High-risk characteristics included
age >75 years, diabetes, ST-segment elevation within 7 days,
or unstable angina within 48 h. The high-risk group demon-
strated a reduction in the combined end point of death or
myocardial infarction at both 30 days (6.2% v/s 12.4%;
p < 0.001) and 12 months (8.0% v/s 15.9%; p < 0.001).9 The low-
risk group demonstrated a trend toward benefit but did not
achieve a statistically significant improvement with Eptifiba-
tide thereby suggesting that higher risk groups benefit more.
In our patient population, the GpRO achieved based on the-day major adverse clinical event across Eptifibatide group
Group T, n ¼ 108 T value p Value
38.2%  20.7% 4.3 <0.001
38.8%  18.8% 9.1 <0.001
0.4% 7.6 <0.01
38.5%  22.2% (n ¼ 16) 2.9 <0.01
37.6%  22.9% (n ¼ 24) 3.4 <0.01
30.9%  17.3% (n ¼ 32) 9.5 <0.001
43.7%  18% (n ¼ 60) 2.3 <0.05
11.6% 3.5 p ¼ 0.06
clinical event end points of recurrent ischemia, reinfarction, target
for cardiovascular (CV) causes and CV Death.
Table 3 e Subgroups analysis of Glycoprotein IIb/IIIa receptor occupancy ratio and 30-day major adverse clinical event,
across the four subgroups.
Results Group EB, n ¼ 48 Group EB þ Inf, n ¼ 44 Group TAdv, n ¼ 12 Group TStd, n ¼ 96 p Value
Absolute GpRO 62.7%  27.2% 61.4%  6.1% 68.8%  27.3% 35.1%  17.7% <0.001a
GpRO >80% 9% 13% 4% 0% <0.001a
30-Day MACE 4.2% 4.5% 8.3% 12.5% NSa
Group EB ¼ Eptifibatide two intracoronary bolus alone; Group EB þ Inf ¼ Eptifibatide intravenous bolus followed by infusion; Group
TStd ¼ Tirofiban standard dose; Group TAdv ¼ Tirofiban ADVANCE trial dose; MACE ¼ Major adverse clinical event end points of recurrent
ischemia, reinfarction, target vessel revascularization, worsening heart failure, repeat hospitalization for Cardiovascular (CV) causes and CV
Death.
a No statistical difference was seen between Groups EB, EB þ Inf and TAdv and statistically significant difference was seen when Group TStd was
compared with Groups EB, EB þ Inf and TAdv.
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(51.12%  23.75%) as compared to the NSTEMI patients
(38.61%  22.74%), however, in the presence of visible
thrombus the GpRO was significantly lower as compared to
without visible thrombus. This suggests that the NSTEMI
patients having visible thrombus are more resistant to the of
GpIIb/IIIa receptor antagonist used especially with Tirofiban.
The Intra Coronary Eptifibatide (ICE) Trial showed intra-
coronary bolus administration of Eptifibatide during PCI in
patients with acute coronary syndromes results in higher
local platelet GpIIb/IIIa receptor occupancy, which is associated
with improved microvascular perfusion. They also showed
that platelet GpIIb/IIIa receptor occupancy was significantly
greater with intracoronary v/s intravenous administration:
first bolus, 94 9% v/s 51 15% (p< 0.001).10,11 In our study too
the results with intracoronary Eptifibatide bolus alone regime
was comparable to the traditional intravenous bolus plus
infusion (absolute GpRO in subgroup EB was 62.7%  27.2%
while in subgroup EB þ Inf was 61.4%  6.1%); and also had
a similar incidence of 30-day MACE (subgroup EB 4.2% and
subgroup EB þ Inf 4.5%), thereby stating that using intra-
coronary bolus alone can become a preferred strategy;
wherein we can do away with the infusion regime especially
after using high loading dose of Clopidogrel. These beneficial
effects may be explained by high local concentrations of
Eptifibatide, which lead to the disaggregation of thrombi at the
site of the ruptured plaque and in the microcirculation. Since
Eptifibatide is a competitive inhibitor of fibrinogen binding to
the platelet GpIIb/IIIa receptor, the presence of high localized
concentrations of drug may enable the dissociation of bound
fibrinogen that cross links activated platelets to form the
occlusive thrombus. Hence, microvascular perfusion may be
improved by reducing both the number and the size of
microemboli. Studies have demonstrated that Eptifibatide
disaggregates thrombi more effectively at higher concentra-
tions with an order of magnitude greater than that usually
achieved with standard intravenous administration.
The present study although is limited by its small number
and a heterogeneous group of patients, who were included
with variable baseline characteristics and a non-randomized
enrollment. However, this study was intended to be a concept
building study and the results have to be further validated in
a large series of patients.
Therefore to conclude, as compared to Eptifibatide, Tir-
ofiban results in significantly lower rates of GpIIb/IIIa receptoroccupancy ratio. The incidence of MACE was lower with
Eptifibatide and higher dose of Tirofiban as compared to the
standard dose of Tirofiban. Eptifibatide intracoronary bolus
alone achieved similar efficacy as compared to the standard
regime of intravenous bolus plus infusion.Conflicts of interest
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